Henagliflozin

Phase 3Small molecule

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Henagliflozin is one of 188 small molecule programs targeting Myocardial fibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

187

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial FibrosisActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Diabetic NephropathyActive, not recruiting

Type 2 DiabetesActive, not recruiting

MetforminUnknown status

FibrosisNot yet recruiting

Weight LossNot yet recruiting

PrediabetesNot yet recruiting

Myocardial FibrosisPreclinical

Active, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Diabetic NephropathyPreclinical

Active, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

MetforminPreclinical

Unknown status

FibrosisPhase 3

Not yet recruiting

Weight LossPhase 3

Not yet recruiting

PrediabetesPhase 3

Not yet recruiting

Competition

Competitive Landscape

171 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3

1 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

Routine Treatment

GSK

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Weight Loss

NCT06216340

Post-ApprovalNot yet recruiting

Fibrosis

NCT06762223

Q4 2027

Post-ApprovalNot yet recruiting

Prediabetes

NCT06448130

Q4 2028

N/ANot yet recruiting

Myocardial Fibrosis

NCT07294495

Clinical

Trials by Indication[1]

Non-Alcoholic Fatty Liver Disease1 trial

Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

Unknown status·SSir Run Run Shaw Hospital·Phase 4·NCT06218342·156 enrolled

Metformin1 trial

The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

Unknown status·RRenJi Hospital·N/A·NCT06059287·64 enrolled

Myocardial fibrosis1 trial

Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR

Not yet recruiting·SShanghai East Hospital·N/A·NCT07294495·150 enrolled

Type 2 Diabetes1 trial

Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05742230·1,932 enrolled

PreDiabetes1 trial

Henagliflozin's Impact on Prediabetes Remission

Not yet recruiting·SShandong Provincial Hospital·Phase 4·NCT06448130·984 enrolled

6 more indications

Fibrosis1 trial

Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM

Not yet recruiting·XXiqiao Zhou·Phase 4·NCT06762223·190 enrolled

Diabetic Nephropathy1 trial

Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis

Unknown status·QQianfoshan Hospital·N/A·NCT06031389·120 enrolled

Weight loss1 trial

Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes

Not yet recruiting·TThe First People's Hospital of Changzhou·Phase 4·NCT06216340·300 enrolled

Completed·QQian geng·Phase 4·NCT06187727·248 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Henagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Henagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Henagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Henagliflozin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Trials by Indication[1]

Non-Alcoholic Fatty Liver Disease1 trial

Metformin1 trial

Myocardial fibrosis1 trial

Type 2 Diabetes1 trial

PreDiabetes1 trial

Fibrosis1 trial

Diabetic Nephropathy1 trial

Weight loss1 trial

Cognitive impairment1 trial

Infusion1 trial

Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News